From: Mortality risk after clinical management of recurrent and metastatic adenoid cystic carcinoma
Overall | LRR | DM | p value | |
---|---|---|---|---|
Characteristic | 36 | 20 | 16 | |
Ethnicity | ||||
White (incl. Hispanic) | 25 (69.4%) | 10 (50.0%) | 15 (93.8%) | 0.02 |
Asian/Pacific-Islander | 8 (22.2%) | 7 (35.0%) | 1 (6.3%) | |
African-American | 1 (2.8%) | 1 (5.0%) | 0 | |
Other | 2 (5.6%) | 2 (10.0%) | 0 | |
Female | 24 (66.7%) | 13 (65.0%) | 11 (68.8%) | 0.55 |
Male | 12 (33.3%) | 7 (35.0%) | 5 (31.3%) | |
Initial Stage | 0.38 | |||
I-II | 5 (22.7%) | 1 (12.5%) | 4 (28.6%) | |
III-IV | 15 (77.3%) | 7 (87.5%) | 10 (71.4%) | |
Unknown | 14 | 12 | 2 | |
Initial Treatment | ||||
Surgery | 7 (19.4%) | 6 (30.0%) | 1 (6.3%) | 0.08 |
Surgery + PORT | 29 (80.6%) | 14 (70.0%) | 15 (93.8%) | |
Age at recurrence, Median (IQR) | 64 (44–74) | 66 (47–76) | 60 (42–70) | 0.48 |
Months to recurrence after initial treatment, Median (IQR) | 50 (16–88) | 51 (15–108) | 50 (18–77) | 0.58 |
Low-risk | 14 (38.9%) | 9 (45.0%) | 5 (31.3%) | 0.31 |
High-risk | 22 (61.1%) | 11 (55.0%) | 11 (68.8%) |